News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
716,052 Results
Type
Article (43467)
Company Profile (356)
Press Release (672229)
Section
Business (211603)
Career Advice (2086)
Deals (36350)
Drug Delivery (93)
Drug Development (82101)
Employer Resources (172)
FDA (16655)
Job Trends (15271)
News (355615)
Policy (33328)
Tag
Academia (2683)
Alliances (52179)
Alzheimer's disease (1272)
Approvals (16587)
Artificial intelligence (164)
Bankruptcy (357)
Best Places to Work (11860)
Biotechnology (253)
Breast cancer (180)
Cancer (1332)
Cardiovascular disease (107)
Career advice (1744)
Cell therapy (283)
Clinical research (65368)
Collaboration (462)
Compensation (247)
COVID-19 (2623)
C-suite (112)
Data (1373)
Diabetes (164)
Diagnostics (6432)
Earnings (86477)
Employer resources (151)
Events (114816)
Executive appointments (372)
FDA (17292)
Funding (424)
Gene therapy (203)
GLP-1 (608)
Government (4433)
Healthcare (19403)
Infectious disease (2713)
Inflammatory bowel disease (113)
Interviews (320)
IPO (16667)
Job creations (3814)
Job search strategy (1491)
Layoffs (428)
Legal (8077)
Lung cancer (188)
Manufacturing (198)
Medical device (13934)
Medtech (13939)
Mergers & acquisitions (19813)
Metabolic disorders (438)
Neuroscience (1588)
NextGen Class of 2024 (6833)
Non-profit (4603)
Northern California (1657)
Obesity (252)
Opinion (193)
Patents (119)
People (58607)
Phase I (20482)
Phase II (28764)
Phase III (21367)
Pipeline (504)
Postmarket research (2578)
Preclinical (8802)
Radiopharmaceuticals (254)
Rare diseases (255)
Real estate (6216)
Regulatory (22193)
Research institute (2449)
Resumes & cover letters (362)
Southern California (1441)
Startups (3827)
United States (15085)
Vaccines (588)
Weight loss (180)
Date
Today (125)
Last 7 days (699)
Last 30 days (2942)
Last 365 days (36385)
2024 (35347)
2023 (41143)
2022 (52406)
2021 (56999)
2020 (55617)
2019 (48412)
2018 (36446)
2017 (33548)
2016 (33152)
2015 (39368)
2014 (32952)
2013 (28003)
2012 (30257)
2011 (30877)
2010 (28835)
Location
Africa (755)
Arizona (203)
Asia (39908)
Australia (6635)
California (3747)
Canada (1409)
China (293)
Colorado (173)
Connecticut (176)
Europe (87161)
Florida (515)
Georgia (138)
Illinois (389)
Indiana (222)
Kansas (99)
Maryland (626)
Massachusetts (2960)
Michigan (184)
Minnesota (293)
New Jersey (1079)
New York (1056)
North Carolina (774)
Northern California (1657)
Ohio (146)
Pennsylvania (910)
South America (1149)
Southern California (1441)
Texas (539)
Utah (110)
Washington State (400)
716,052 Results for "myos rens technology inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
March 27, 2024
·
5 min read
Pharm Country
DC Medicaid Becomes the First Medicaid Plan to Cover the Nerivio® REN Wearable, a Non-Drug Treatment for Migraine
Theranica, a neuromodulation therapeutics company, today announced DC Medicaid’s coverage of the Nerivio® REN wearable, the first and only FDA-cleared, non-drug, non-disruptive treatment for both acute attacks and prevention of migraine with or without aura in adolescents and adults ages 12 and older.
May 21, 2024
·
4 min read
Press Releases
More States Join the Movement: The Nerivio® REN Wearable Now Covered by Arizona, New Jersey, Ohio, and Virginia Medicaid Programs
October 1, 2024
·
5 min read
Policy
MYOS RENS Technology Inc. Announces Settlement of Litigation with RENS Technology Inc.
MYOS RENS Technology Inc. (“MYOS” or the “Company”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced that it has settled its pending litigation with RENS Technology Inc. and its president,
July 16, 2020
·
6 min read
Xinhua Silk Road: Pien Tze Huang, Beijing Tong Ren Tang agree to boost bilateral cooperation, promote high-quality development of TCM
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. signed a cooperation agreement with Beijing Tong Ren Tang Group during the First Conference of Partners of Tong Ren Tang, which was held in Beijing from January 17 to 19.
February 1, 2024
·
1 min read
Deals
MedAvail and MYOS RENS Technology Announce Closing of Business Combination
MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc. (NASDAQ: MYOS), an adva
November 18, 2020
·
5 min read
Press Releases
New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12
July 25, 2024
·
4 min read
Deals
MYOS RENS TECHNOLOGY BOARD OF DIRECTORS approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding
MYOS RENS Technology Inc. (“MYOS” or the “Company”) (NASDAQ: MYOS) As previously announced, on June 30, 2020 , MYOS RENS Technology, Inc., a Nevada corporation (“MYOS”), and MedAvail, Inc
November 17, 2020
·
7 min read
Pharm Country
MYOS RENS Technology, Inc. Appoints The S3 Agency to Help Build Awareness of Muscle Health Importance
MYOS RENS Technology, Inc. (“MYOS”) (NASDAQ: MYOS), “The Muscle Health Company” and owner of the advanced nutrition supplement Fortetropin®, announced today that it has hired The S3 Agency (S3)
September 9, 2020
·
5 min read
Business
MYOS RENS Technology Announces Net Revenues Increase 39% for the Three Months Ended September 30, 2020
MYOS RENS Technology Inc. (“MYOS” or the “Company”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, announced today its results fo
November 6, 2020
·
12 min read
1 of 71,606
Next
